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Introduction: Neuroglycopenia is recognized to be associated with abnormal neurode-
velopmental outcomes in 26–44% of children with persistent congenital hyperinsulinism
(P-CHI). The prevalence of abnormal neurodevelopment in transient CHI (T-CHI) is not
known. We have aimed to investigate abnormal neurodevelopment and associated fac-
tors in T-CHI and P-CHI.
Materials and Methods: A cohort of children with CHI (n=67, age 2.5–5 years) was
assessed at follow-up review and noted to have normal or abnormal (mild or severe) neu-
rodevelopmental outcomes for the domains of speech and language, motor, and vision.
Children were classified as P-CHI (n=33), if they had undergone surgery or remained on
medical therapy, or T-CHI (n=34), if medical treatment for hypoglycemia was stopped.
Results: Overall, abnormal neurodevelopment was present in 26 (39%) children with CHI,
of whom 18 (69%) were severe. Importantly, the incidence of abnormal neurodevelopment
in T-CHI was similar to that in P-CHI (30 vs. 47% respectively, p=0.16). The prevalence of
severe abnormal neurodevelopment in speech, motor, and vision domains was similar in
bothT-CHI and P-CHI children. For this cohort, we found that the severity of disease [based
upon maximal diazoxide dose (odds ratio 95% confidence intervals) 1.3 (1.1; 1.5), p=0.03],
and early presentation of CHI <7 days following birth [5.9 (1.3; 27.8), p=0.02] were signif-
icantly associated with abnormal neurodevelopment. There was no significant association
with gender, genotype, or the histopathological basis of CHI.
Conclusion: Abnormal neurodevelopment was evident in one third of children with both
T-CHI and P-CHI, early presentation and severe CHI being risk factors. Early recognition and
rapid correction of hypoglycemia are advocated to avoid abnormal neurodevelopment in
children with CHI.
Keywords: congenital hyperinsulinism, hypoglycemia, neurodevelopment, developmental delay, neurological
outcome, seizures, transient congenital hyperinsulinism
BACKGROUND
Congenital Hyperinsulinism (CHI) is caused by dysregulated
excessive insulin secretion leading to profound and unpredictable
hypoglycemia, often in early childhood. Severe hypoglycemia in
CHI can lead to neuroglycopenia in the brain, associated with sup-
pression of other metabolites such as ketones or lactate, which usu-
ally preserve neuronal function in the absence of glucose (Arnoux
et al., 2012; Senniappan et al., 2012). However, the association of
developmental delay and epilepsy in children with diabetes with
DEND syndrome (developmental delay, epilepsy, and neonatal
diabetes) also raises the possibility that gene defects common to the
pancreas and the CNS can contribute to altered neurological func-
tion (Gloyn et al., 2006). Abnormal neurodevelopmental outcomes
with a tendency to motor and speech delay in early childhood have
been recognized in children with persistent CHI (P-CHI) (Arnoux
et al., 2012) with incidence varying between 26 and 44% in rel-
atively large and well characterized cohorts of patients (Menni
et al., 2001; Meissner et al., 2003; Ludwig et al., 2011). The preva-
lence of abnormal neurodevelopment and seizures appears to be
particularly high in CHI associated with hyperammonemia (Bahi-
Buisson et al., 2008; Kapoor et al., 2009), while infantile spasms, a
rare seizure disorder, has also been described in children with P-
CHI (Kumaran et al., 2010). In contrast, a significant proportion
(up to 50%) of children with CHI, achieve spontaneous resolu-
tion without a long-term need for medication and/or surgery;
transient CHI (T-CHI) (Banerjee et al., 2011). Yet, only one single
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case report has described T-CHI with unfavorable neurological
outcome (Vercellino et al., 2011), and there are no reports of
neurodevelopmental outcomes in cohorts of children. Given the
high prevalence of transient disease in the population of children
with CHI we sought to assess neurodevelopment outcomes and
compare these with data from patients with P-CHI.
AIMS
1. To test the hypothesis that the early childhood incidence of
abnormal neurodevelopment is greater in children with P-CHI
than in T-CHI.
2. To investigate factors associated with an increased risk of
abnormal neurodevelopment in patients with T-CHI and
P-CHI.
METHODS
The clinical notes of a cohort of children with CHI (n= 67),
were examined retrospectively to assess abnormal neurodevelop-
ment. The diagnosis of CHI was made using established criteria
(Arnoux et al.,2012; Banerjee et al.,2011). All children had received
diazoxide as first line treatment of CHI. Patients with perinatal
asphyxia, prematurity<32 weeks or intraventricular hemorrhages
were excluded from the study. Only those children within the age
range 2.5–5 years were chosen for review. The lower age limit
ensured that the child was old enough for abnormal neurode-
velopmental outcomes to be manifest in routine clinical review.
Childhood development was assessed at 6 months after the diag-
nosis of CHI, initially by a pediatric endocrinologist at our CHI
Treatment. If developmental assessment was initially reported as
normal, the child’s most recent appointment at a multidiscipli-
nary CHI clinic was reviewed for evidence of possible abnormal
neurodevelopment. If abnormal, a referral was made to a local
community pediatrician for a formal developmental assessment.
These assessments were analyzed retrospectively to derive a sum-
mated score of mild or severe abnormal neurodevelopment, based
on observations in the following developmental domains: speech
and language, motor, and vision (Meissner et al., 2003). While mild
abnormal neurodevelopment was indicated by the presence of any
neurological deficit or developmental delay, not within normal
limits, severe abnormal neurodevelopment was indicated by the
presence of significant functional impairment requiring sustained
supportive therapy at home and at school.
Note was made if any child had had recurrent seizures beyond
the first week after diagnosis, and if lower limb weakness was
present (unilateral or bilateral). If infantile spasms were suspected,
they were confirmed by the finding of hypsarrhythmia patterns
in electroencephalography. Where available, brain magnetic reso-
nance (MR) imaging results were noted. The long-term follow up
of children with abnormal neurodevelopment was not recorded
for this study. Formal psychometric testing was not performed
in these children as this method of testing is reserved for those
children older than 6 years in our Center.
All children were tested for ABCC8/KCNJ11 mutations and
other CHI-causing genes. All children who underwent surgery
were diagnosed with focal or diffuse disease. Maximal dose of dia-
zoxide (mg/kg/day) was recorded as a surrogate marker of severity
of CHI, with greater dosage indicating a more severe disease
(Banerjee et al., 2011). In addition, treatment with glucagon infu-
sion to achieve glycemic stability and carbohydrate requirement
(mg/kg/min) were recorded as severity markers, although the lat-
ter was recorded only in those with neonatal presentation, and not
in those with late-presenting CHI.
Persistent congenital hyperinsulinism was defined in those chil-
dren who remain on diazoxide or other medication or required
pancreatectomy (focal or subtotal) to treat hypoglycemia. T-CHI
was defined in those cases where hypoglycemia has resolved spon-
taneously and all medications have been discontinued to date
(Banerjee et al., 2011).
Chi square and Fisher’s exact tests were used to test the dif-
ference between proportions, such as the incidence of abnor-
mal neurodevelopment in P-CHI and T-CHI. Backward logistic
regression models were used to test the association of covari-
ates on binary outcomes, such as developmental outcome which
was classified as either abnormal neurodevelopment or normal
neurodevelopment.
RESULTS
In the whole cohort (n= 67), the median (range) age at diagnosis
was 2 (1; 630) days, with insulin levels of 18.2 (2.1; 335.9) mU/l and
glucose levels of 1.6 (0.1; 2.6) mmol/l. Maximum dose of diazoxide
was 8.6 (4.5; 25.0) mg/kg/day, while glucagon infusion for initial
glycemic stabilization was required in 13 (19%) children. In those
with neonatal presentation, carbohydrate requirement was 18 (8;
25) mg/kg/min. There was a preponderance of males (n= 48,
72%) in the cohort. Birth weight was variable at 3.3 (1.2; 5.5)
kg, with prematurity (32–37 weeks gestation) present in 13 (19%).
The total number of CHI related mutations was 22 (33%), of which
the majority were KATP channel gene mutations (n= 19). Other
mutations included one each for GCK, HADH, and PHOX2B.
CHI OUTCOMES: T-CHI AND P-CHI
Focal lesionectomy was performed in four children with focal CHI
(6% of the cohort), and subtotal pancreatectomy was required
for the treatment of medically unresponsive diffuse CHI in eight
children (12% of the cohort). Spontaneous resolution of hypo-
glycemia occurred in children with T-CHI (n= 33, 49%), at a
median (range) time of 119 (14; 700) days, while symptoms were
sustained in P-CHI (n= 34, 51%) at a follow-up of 1187 (270;
4678) days. Clinically relevant diagnostic and treatment charac-
teristics of children with T-CHI and P-CHI are given in Table 1.
Early onset of CHI, i.e., age at presentation<7 days was more fre-
quent in those with T-CHI. As expected, the presence of genetic
mutations and the maximum dose of diazoxide were lower in those
with T-CHI.
NORMAL AND ABNORMAL NEURODEVELOPMENTAL OUTCOMES
Abnormal neurodevelopment was noted in 26 (39%) children in
the whole cohort, with 8 (12%) children being mild and 18 (27%)
children in the severe category. Within the abnormal neurodevel-
opment group, the prevalence of speech and language, motor and
vision abnormalities, seizures, infantile spasms, and lower limb
weakness is described in Table 2. Visual abnormalities, lower limb
weakness, and infantile spasms occurred more frequently in those
with severe abnormal neurodevelopment. The prevalence of severe
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Table 1 | Diagnostic and treatment characteristics of children withT-CHI and P-CHI: categorical variables are represented as numbers of patients
and as a percentage (%) of the cohort, while continuous variables are represented as median (range) values.
T-CHI (n=33) P-CHI (n=34) pValue for difference
Presentation <7 days, n (%) 30 (91%) 21 (62%) 0.009
Serum insulin at diagnosis (mU/l) 10.6 (2.1; 335.9) 18.2 (3; 132) 0.16
Serum glucose at diagnosis (mmol/l) 1.4 (0.1; 2.6) 1.6 (0.2; 2.6) 0.59
CHI-causing mutations, n (%) 4 (12%) 18 (53%) <0.001
Carbohydrate requirement (mg/kg/min) 14 (8; 18.7) 18 (12.7; 21.0) 0.20
Numbers of patients requiring glucagon infusion, n (%) 6 (18%) 7 (20%) 0.80
Maximum dose of diazoxide requirement (mg/kg/day) 6.0 (5; 15) 15 (5; 25) <0.001
Table 2 | Mild and severe abnormal neurodevelopment characterized in the domains of speech and language, motor, vision, seizures, infantile
spasms, and limb weakness.
Mild abnormal neurodevelopment
n=8 children
Severe abnormal neurodevelopment
n=18 children
pValue for difference
Speech and language, n (%) 7 (87) 18 (100) 0.12
Motor, n (%) 6 (75) 18 (100) 0.08
Vision, n (%) 0 (0) 10 (56) 0.009
Seizures, n (%) 3 (37) 9 (50) 0.68
Infantile spasms, n (%) 0 (0) 4 (29) 0.26
Lower limb weakness, n (%) 0 (0) 8 (44) 0.03
abnormal neurodevelopment was similar in those presenting <7
or >7 days of age [16 (70%) vs. 2 (67%), p= 0.9].
Brain MR scanning was performed in 15 children with abnor-
mal motor neurodevelopment, severe cognitive dysfunction, and
seizures. Significant MR changes such as parietal infarcts, occipital
high signal intensities, gliosis, infarctions, periventricular leuko-
malacia, basal ganglia changes, white matter atrophy, and sagittal
sinus thrombosis were noted in 11 (73%) children. Such changes
were present in children with T-CHI and P-CHI with similar fre-
quencies [7 (87%) vs. 4 (57%), p= 0.18] but with a predictably
greater frequency in those with severe abnormal neurodevelop-
ment [10 (91%) vs. 1 (25%), p= 0.03]. The MR scan of one child
with T-CHI with severe abnormal neurodevelopment outcome is
shown in Figure 1. Two children with P-CHI, one with a focal
lesion due to paternal ABCC8 mutation, and the other with a
paternally inheritedGCK mutation, developed autism, but did not
have MR changes. Severe abnormal neurodevelopment was not
observed in siblings of children with CHI, negating the possibility
of familial neurodevelopmental disorders.
The proportion of children with abnormal neurodevelopment
in T-CHI was not significantly different from those in P-CHI
[10 (30%) vs. 16 (47%), p= 0.15]. Further, the prevalence of
severe abnormal neurodevelopment in patients with T-CHI was
similar in those with P-CHI [8 (73%) vs. 10 (62%), p= 0.69]
(Figure 2). These results refute our initial hypothesis that abnor-
mal neurodevelopment occurs more commonly in P-CHI than
T-CHI.
Diagnostic and treatment characteristics of children with nor-
mal and abnormal neurodevelopment are shown in Table 3.
Presentation <7 days was more frequent in children with abnor-
mal neurodevelopment. In children with neonatal presentation
of CHI, carbohydrate requirement was similar in those with nor-
mal and abnormal neurodevelopment [18.0 (11.7; 25.0) vs. 15
(10.0; 25.0) mg/kg/min, p= 0.53]. The maximum dose of dia-
zoxide, but not prematurity, genotype, carbohydrate requirement,
or requirement for glucagon infusion was associated with abnor-
mal neurodevelopment. In backward stepwise logistic regression
(R2= 0.26, p= 0.01), maximum dose of diazoxide [Odds ratio
(95% confidence intervals) 1.3 (1.1; 1.5), p= 0.03] and age at pre-
sentation<7 days [5.9 (1.3; 27.8), p= 0.02], but not other covari-
ates, such as gender, birth weight, prematurity, genotype, glucagon
use, or the incidence of focal CHI were positively correlated with
abnormal neurodevelopment.
DISCUSSION
While abnormal neurodevelopment has been reported in signif-
icant proportions of children with P-CHI (Menni et al., 2001;
Meissner et al., 2003), there are no reports of the incidence of
abnormal neurodevelopment in T-CHI. Here, we report for the
first time that a significant proportion of children with transient
disease – 30% in our cohort, have abnormal neurodevelopment,
often severe and associated with the presence of seizures. There-
fore, although T-CHI may be perceived as a relatively “mild”
illness, the long-term impact of neuroglycopenia causing adverse
neurodevelopment may be significant and under-diagnosed.
It has been suggested that early onset hypoglycemia due to dis-
orders such as CHI may be responsible for later onset epilepsy
in childhood, even if transient in duration (Ng, 2012) and our
findings add further support to this possibility. There is accu-
mulating evidence that the neonatal brain may be susceptible to
injury at a time when CHI usually manifests. In a recent study,
although not in patients with CHI, hypoglycemia in the first 24 h
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FIGURE 1 | Brain MR imaging in a 1-year-old girl with transient CHI,
showing occipital lobe atrophy (OLA) and periventricular high signal
intensities (PVHSI) in sagittalT2 FLAIR sequence scanning (1a) and
occipital hyperintense signals (OHS) within subcortical white matter in
proton density andT2 axial images, the latter being highly suggestive of
hypoglycemic injury.
FIGURE 2 |The severity of abnormal neurodevelopment in patients
with CHI. Mild and severe abnormal neurodevelopment for both persistent
(P-CHI) and transient CHI (T-CHI); the prevalence of severe abnormal
neurodevelopment is similar in both groups, implying that early severity, but
not the duration of hypoglycemia is important in determining the outcome
of hypoglycemia in children with CHI.
after birth increased the probability of corticospinal tract damage
3.7-fold in neonates at risk of encephalopathy (Tam et al., 2012).
Further, it has been noted that the presence of co-morbidities
increases the likelihood of abnormal neurodevelopment in sev-
eral disorders of hypoglycemia, including CHI (Gataullina et al.,
2012). It is likely that neuroglycopenia in the early neonatal period
may be a significant risk factor for abnormal neurodevelopment
and that the first few weeks of life may represent an opportunity
for aggressive correction of hypoglycemia to improve long-term
outcomes in children with CHI, particularly as there is emerg-
ing evidence that the topography of brain injury is determined
by the age of hypoglycemic insult (Gataullina et al., 2013). This
therapeutic opportunity applies to children with both T-CHI
and P-CHI and may apply to other conditions with neonatal
hypoglycemia.
The overall incidence of abnormal neurodevelopment in chil-
dren with P-CHI is similar to other studies over the last decade
(Menni et al., 2001; Meissner et al., 2003; Ludwig et al., 2011), sug-
gesting that despite major advances in the diagnosis and treatment
of CHI, adverse neurodevelopmental outcome has not improved
significantly. Although it has been suggested that satisfactory long-
term neurological outcomes can be achieved in some popula-
tions of patients treated conservatively without pancreatectomy
(Mazor-Aronovitch et al., 2007), on closer scrutiny of this study
involving relatively small patient numbers (n= 21), 38% children
required support for developmental delay in early life and 29%
had learning problems later in school, implying that abnormal
neurodevelopment rates were similar to other larger studies.
In our cohort the association of abnormal neurodevelopment
with an early neonatal presentation is consistent with the report of
Menni et al. (2001), but contradicts the findings of another study
in 114 patients, which indicated that the correlation of abnormal
neurodevelopment in P-CHI occurred with infancy-onset disease
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Table 3 | Diagnostic and treatment characteristics in children with normal and abnormal neurodevelopment: categorical variables are
represented as numbers of patient and as a percentage (%) of the cohort, while continuous variables are represented as median (range).
Normal neurodevelopment
n=41 children
Abnormal neurodevelopment
n=26 children
pValue for difference
Presentation <7 days, n (%) 28 (68) 23 (89) 0.05
Insulin at diagnosis (mU/l) 13.4 (2.1; 335.9) 15.1 (3.2; 92) 0.52
Glucose at diagnosis (mmol/l) 1.6 (0.1; 2.6) 1.5 (0.2; 2.5) 0.61
CHI-causing mutations, n (%) 13 (32) 9 (35) 0.80
Carbohydrate requirement (mg/kg/min) 18 (8; 25) 15 (10; 25) 0.65
Number of patients requiring glucagon infusion, n (%) 7 (17%) 6 (23) 0.54
Maximum dose of diazoxide (mg/kg/day) 6.6 (2.0; 15.0) 10.0 (5.0; 25.0) 0.05
Focal CHI, n (%) 1 (2) 3 (11) 0.12
Time to spontaneous resolution (T-CHI), days 119 (14; 700) 163 (90; 699) 0.09
(Meissner et al., 2003). The difference could be explained by a bias
in patient selection, delayed diagnosis in the infantile-onset group
and the inherent variability in the retrospective analyses of ques-
tionnaires which were used to assess psychomotor development.
It may be noted that there was no difference in the incidence of
severe abnormal neurodevelopment presenting before or after the
age of 7 days in our cohort.
In keeping with a case series (Kumaran et al., 2010), we found a
disproportionate representation of children with infantile spasms
in our cohort. It is possible that early onset hypoglycemia is a risk
factor for the later development of hypsarrhythmias, although it is
possible that common factors underpin the development of CHI
and neuronal abnormalities. Studies in larger cohorts are required
to confirm the association.
Our findings have weaknesses inherent to any observational
study. The design was retrospective, the developmental assess-
ments were not standardized and performed opportunistically
at any time 6 months after diagnosis of CHI. However, the fact
that the prevalence of neurological complications is broadly in
keeping with other studies implies that the presence of abnor-
mal neurodevelopment was appropriately detected in our study.
It is possible that the study protocol under-reported the presence
of mild abnormal neurodevelopment. However, it is unlikely that
severe cases of abnormal neurodevelopment were missed, as all
cases with normal neurodevelopment were subsequently reviewed
by a clinical psychologist. Ideally, a prospective, formal cognitive,
and psychomotor testing protocol in all patients from diagnosis
would be preferred. However, this is likely to be resource intensive
and time consuming, in contrast to our retrospective and obser-
vational study protocol. Further, it might have been difficult to
capture abnormal neurodevelopment in T-CHI patients, as some
children achieved spontaneous resolution late. It is well recog-
nized that T-CHI may resolve later, with reports of resolution up
to 8 years of age (Banerjee et al., 2011); indeed, the very late resolu-
tion of hypoglycemia also implies that some children with P-CHI
at this time may possibly be categorized as T-CHI at a later date.
In our study, brain MR scanning was not performed routinely;
instead scans were requested on the basis of clinical need. In those
with abnormal neurodevelopment, MR scan was informative, but
not diagnostic of the abnormal neurodevelopment. Further, in
some children, MR scanning did not show anatomical abnor-
malities, suggesting that brain imaging may be complimentary
but not independently useful in the neurodevelopmental assess-
ment of children with CHI, although recent evidence suggests that
the timing of hypoglycemic injury may influence the anatomical
distribution of brain damage (Gataullina et al., 2013).
The correlation of abnormal neurodevelopment with diazox-
ide dose as a marker of severity is interesting and novel. Although
maximum carbohydrate requirement at diagnosis might be the
rational marker of choice denoting severity of hypoglycemia, this
measurement cannot always be determined, as supported by evi-
dence from other studies (Meissner et al., 2003). This is because
the glucose content of food in the post-weaning period cannot be
reliably calculated, unless nutrition is prescribed for gastrostomy
feeding or the child is on intravenous fluids. Although we did
record carbohydrate intake, we used escalating doses of diazoxide
as a surrogate marker of insensitivity to the drug and therefore of
the severity of CHI. Theoretically, it is possible that the positive
correlation of diazoxide dose and abnormal neurodevelopment
indicates that diazoxide itself may be detrimental to the neona-
tal brain. However, there have been no clinical reports of brain
injury from diazoxide use, and there are several studies in animals
demonstrating neuroprotective effects of diazoxide (Zhang et al.,
2010, Huang et al., 2010). It is possible that diazoxide unrespon-
siveness represents an independent adverse marker for abnormal
neurodevelopment, due to relative drug inactivity at the level of
neuronal KATP channels, which are important for brain neuronal
survival. Further work in animal models and correlation in human
beings is required to evaluate the independent role of brain KATP
channels in the pathogenesis of abnormal neurodevelopment.
CONCLUSION
Abnormalities in childhood development are common in children
with transient forms of CHI, with about a third being affected.
This rate is similar to that in children with persistent forms of the
disease. Severe and early onset hypoglycemia may adversely influ-
ence later neurodevelopmental outcomes. Therefore, in children
with CHI, early recognition of hypoglycemia, followed by rapid
correction may improve the morbidity of learning and physical
disabilities in later life.
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